Acute graft-versus-host disease (GVHD) remains the major barrier to allogeneic bone marrow transplantation (allo-BMT). Evidence has accumulated that transforming growth factor β1-treated dendritic cells (TGFβ-DC), deficient in surface costimulatory molecules, inhibit alloantigen-specific T-cell responses and induce graft hyporeactivity. To analyze the effect of TGFβ-DC on GVHD after allo-BMT, 5.0 × 106 recipient-derived TGFβ-DC were injected into C57BL/6 (H-2b) with bone marrow-splenocyte grafts from major histocompatibility complex (MHC) disparate BALB/c mice (H-2d). Survival analysis showed TGFβ-DC cotransplantation resulted in significant prolongation of allograft survival, namely a mean survival time (MST) of 44.3 ± 4.5 days, versus the untreated MST of 9.5 ± 0.6 days (P < .01). However, mature DC aggravated the GVHD with an MST of 6.6 ± 0.6 days (P < .01). In addition, the third-party C3H-derived TGFβ-DC did not enhance the survival rate (MST = 9.7 ± 0.5 days). Furthermore, serum IFN-γ, IL-12, and IL-18 levels in TGFβ-DC cotransplanted mice were reduced compared with untreated BMT hosts, while serum IL-10 levels were not changed. These results suggest that TGFβ-DC cotransplantation may attenuate the severity of GVHD after BMT.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Jun 1 2004|
ASJC Scopus subject areas